Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-06-23 4:00 pm Sale | 2026-06-14 | 13D | SILEXION THERAPEUTICS CORP SLXN | Moringa Sponsor, LP | 199,053 10.600% | -1,183,293![]() (-85.60%) | Filing History |
| 2026-05-29 4:00 pm Purchase | 2026-05-14 | 13D | SILEXION THERAPEUTICS CORP SLXN | Moringa Sponsor, LP | 1,382,346 32.990% | 1,336,464![]() (+2912.83%) | Filing History |
| 2026-05-15 4:13 pm Unchanged | 2026-03-31 | 13G | SILEXION THERAPEUTICS CORP SLXN | Lind Global Fund III LP | 21,250 4.960% | 0 (Unchanged) | Filing History |
| 2026-02-13 4:49 pm Purchase | 2025-12-31 | 13G | SILEXION THERAPEUTICS CORP SLXN | Mitchell P. Kopin | 32,500 9.400% | 8,023![]() (+32.78%) | Filing History |
| 2025-11-14 4:09 pm Sale | 2025-09-30 | 13G | SILEXION THERAPEUTICS CORP SLXN | Lind Global Fund III LP | 21,250 6.400% | -1,155![]() (-5.16%) | Filing History |
| 2025-09-23 11:17 am Purchase | 2025-09-15 | 13D | SILEXION THERAPEUTICS CORP SLXN | Moringa Sponsor, LP | 45,882 14.670% | 44,351![]() (+2896.86%) | Filing History |
| 2025-09-18 5:47 pm Purchase | 2025-09-12 | 13G | SILEXION THERAPEUTICS CORP SLXN | Lind Global Fund III LP | 22,405 9.900% | 22,405![]() (New Position) | Filing History |
| 2025-09-17 5:14 pm Purchase | 2025-09-11 | 13G | SILEXION THERAPEUTICS CORP SLXN | Mitchell P. Kopin | 24,477 9.990% | 23,078![]() (+1649.61%) | Filing History |
| 2025-09-15 5:23 pm Sale | 2025-09-11 | 13G | SILEXION THERAPEUTICS CORP SLXN | Orca Capital AG | 10,943 4.900% | -2,182![]() (-16.62%) | Filing History |
| 2025-09-15 5:19 pm Purchase | 2025-09-11 | 13G | SILEXION THERAPEUTICS CORP SLXN | Orca Capital AG | 13,125 6.200% | 13,125![]() (New Position) | Filing History |
| 2025-09-15 12:31 pm Purchase | 2025-09-12 | 13G | SILEXION THERAPEUTICS CORP SLXN | Lincoln Alternative Strategies LLC | 13,125 6.180% | 13,125![]() (New Position) | Filing History |
| 2025-06-26 4:15 pm Unchanged | 2025-06-26 | 13D | SILEXION THERAPEUTICS CORP SLXN | Wildcat Capital Management LLC | 756 1.300% | 0 (Unchanged) | Filing History |
| 2025-05-13 11:36 am Purchase | 2025-03-31 | 13G | SILEXION THERAPEUTICS CORP SLXN | GOLDMAN SACHS GROUP INC GS | 1,413 2.400% | 665![]() (+88.90%) | Filing History |
| 2025-05-12 12:12 pm Purchase | 2025-03-31 | 13G | SILEXION THERAPEUTICS CORP SLXN | CVI Investments, Inc. | 3,044 4.900% | 784![]() (+34.69%) | Filing History |
| 2025-02-10 5:31 pm Purchase | 2024-12-31 | 13G | SILEXION THERAPEUTICS CORP SLXN | GOLDMAN SACHS GROUP INC GS | 748 6.600% | 748![]() (New Position) | Filing History |
| 2025-01-23 12:19 pm Purchase | 2025-01-15 | 13G | SILEXION THERAPEUTICS CORP SLXN | CVI Investments, Inc. | 2,260 8.500% | 2,260![]() (New Position) | Filing History |
| 2025-01-21 5:49 pm Purchase | 2025-01-15 | 13G | SILEXION THERAPEUTICS CORP SLXN | Mitchell P. Kopin | 1,399 4.990% | 1,399![]() (New Position) | Filing History |
| 2024-11-20 06:15 am Purchase | 2024-08-15 | 13D | SILEXION THERAPEUTICS CORP SLXN | Guangzhou Sino-Israel Bio-Industry Investment Fund LLP | 1,472 13.800% | 1,472![]() (New Position) | Filing History |
| 2024-08-22 6:44 pm Purchase | 2024-08-15 | 13D | SILEXION THERAPEUTICS CORP SLXN | Wildcat Capital Management LLC | 756 10.500% | 756![]() (New Position) | Filing History |
| 2024-08-22 5:23 pm Purchase | 2024-08-15 | 13D | SILEXION THERAPEUTICS CORP SLXN | Moringa Sponsor, LP | 1,531 20.800% | 1,531![]() (New Position) | Filing History |

